JP5837890B2 - 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用 - Google Patents

神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用 Download PDF

Info

Publication number
JP5837890B2
JP5837890B2 JP2012557260A JP2012557260A JP5837890B2 JP 5837890 B2 JP5837890 B2 JP 5837890B2 JP 2012557260 A JP2012557260 A JP 2012557260A JP 2012557260 A JP2012557260 A JP 2012557260A JP 5837890 B2 JP5837890 B2 JP 5837890B2
Authority
JP
Japan
Prior art keywords
fenoterol
tumor
naphthylfenoterol
pharmaceutical composition
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012557260A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522230A (ja
JP2013522230A5 (enExample
Inventor
アービング ダブリュ． ワイネル
アービング ダブリュ． ワイネル
ミシェル ベルニエ
ミシェル ベルニエ
ローレンス ロバート トール
ローレンス ロバート トール
リュシータ アレナス ヒメネス
リュシータ アレナス ヒメネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Publication of JP2013522230A publication Critical patent/JP2013522230A/ja
Publication of JP2013522230A5 publication Critical patent/JP2013522230A5/ja
Application granted granted Critical
Publication of JP5837890B2 publication Critical patent/JP5837890B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012557260A 2010-03-10 2011-03-10 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用 Active JP5837890B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31264210P 2010-03-10 2010-03-10
US61/312,642 2010-03-10
PCT/US2011/027988 WO2011112867A1 (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Publications (3)

Publication Number Publication Date
JP2013522230A JP2013522230A (ja) 2013-06-13
JP2013522230A5 JP2013522230A5 (enExample) 2014-04-17
JP5837890B2 true JP5837890B2 (ja) 2015-12-24

Family

ID=43858307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557260A Active JP5837890B2 (ja) 2010-03-10 2011-03-10 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用

Country Status (7)

Country Link
US (4) US9492405B2 (enExample)
EP (1) EP2544676B1 (enExample)
JP (1) JP5837890B2 (enExample)
AU (2) AU2011224241B2 (enExample)
BR (1) BR112012022552A8 (enExample)
CA (1) CA2791702C (enExample)
WO (1) WO2011112867A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013266235B2 (en) * 2012-05-25 2017-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
EP3125878A4 (en) * 2014-04-03 2017-11-29 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
EP3125877A4 (en) * 2014-04-03 2017-11-22 Mitchell Woods Pharmaceuticals, Inc. Methods of treating melanoma
KR101585619B1 (ko) * 2014-11-20 2016-01-15 주식회사 아모텍 감전보호소자 및 이를 구비한 휴대용 전자장치
US20180042867A1 (en) * 2015-03-06 2018-02-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
WO2017059268A1 (en) * 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
WO2017070052A1 (en) * 2015-10-18 2017-04-27 Onco Therapies Llc Compositions and methods of regulating cancer related disorders and diseases
EP3506926A4 (en) * 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
GB201714736D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
CN114456078B (zh) * 2022-01-19 2022-09-16 汉瑞药业(荆门)有限公司 一种(r)-n-苄基-1-(4-甲氧基苯基)丙-2-胺的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE635889A (enExample)
SE354279B (enExample) 1969-06-13 1973-03-05 Draco Ab
CH556323A (de) 1969-12-12 1974-11-29 Boehringer Sohn Ingelheim Verfahren zur herstellung von neuen naphthylalkylaminen.
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
DE2010883A1 (de) 1970-03-07 1971-09-23 Troponwerke Dinklage & Co, 5000 Köln-Mülheim Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung
AT308139B (de) 1970-07-27 1973-06-25 Degussa Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen
IT1044214B (it) 1971-04-22 1980-03-20 Zambeletti Spa L 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione
JPS532194B2 (enExample) 1973-08-10 1978-01-26
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US6866839B2 (en) 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DE69325454T2 (de) 1992-04-17 2000-01-20 Abbott Laboratories, Abbott Park Taxol-derivate
AU4408897A (en) 1996-07-05 1998-02-02 E.C. Pesterfield Associates, Inc. Method of treating retinal ischemia and glaucoma, using optically pure r- or rr- isomers of adrenergic beta-2 agonists
US6015837A (en) 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
AU9672598A (en) 1997-09-30 1999-04-23 E.C. Pesterfield Associates, Inc. Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
AU6167599A (en) 1998-09-30 2000-04-17 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of a beta2 adrenergic receptor agonist in the treatment of cardiovascular disease
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
MXPA05002113A (es) 2002-08-23 2005-06-03 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios para ellas, analogos y usos de los mismos.
US20050107417A1 (en) 2003-07-28 2005-05-19 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
JP2007510727A (ja) 2003-11-03 2007-04-26 ミオゲン インコーポレイティッド 心血管疾患を治療するための１，４−ジヒドロピリジン化合物、薬学的組成物、および方法
WO2005092333A1 (en) 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
WO2006015830A1 (en) 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
CN101137625A (zh) 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
KR101378067B1 (ko) 2006-08-10 2014-04-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 （ｒ,ｒ）―페노테롤 및 （ｒ,ｒ）―또는 （ｒ,ｓ）―페노테롤 유사체의 제조방법 및 이의 울혈성 심부전증 치료를 위한 용도
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
DK2207537T3 (en) 2007-10-02 2017-10-02 Fremont Group Ltd Systemic pro-haemostatic effect of sympathomimetics with agonistic effects on alpha-adrenergic and / or beta-adrenergic receptors in the sympathetic nervous system, related to improved clot strength
WO2011079279A2 (en) * 2009-12-23 2011-06-30 Board Of Trustees Of The University Of Illinois Nanoconjugates and nanoconjugate formulations

Also Published As

Publication number Publication date
US20200197332A1 (en) 2020-06-25
US9492405B2 (en) 2016-11-15
US10617654B2 (en) 2020-04-14
JP2013522230A (ja) 2013-06-13
US10130594B2 (en) 2018-11-20
AU2014210656B2 (en) 2016-03-17
US10925840B2 (en) 2021-02-23
CA2791702A1 (en) 2011-09-15
AU2011224241B2 (en) 2014-05-08
AU2011224241A1 (en) 2012-09-20
WO2011112867A8 (en) 2012-09-27
EP2544676A1 (en) 2013-01-16
US20170007556A1 (en) 2017-01-12
CA2791702C (en) 2018-05-29
US20190008802A1 (en) 2019-01-10
BR112012022552A8 (pt) 2017-12-05
AU2014210656A1 (en) 2014-08-28
EP2544676B1 (en) 2018-09-19
WO2011112867A1 (en) 2011-09-15
US20130005799A1 (en) 2013-01-03
BR112012022552A2 (pt) 2016-08-30

Similar Documents

Publication Publication Date Title
JP5837890B2 (ja) 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用
JP5302194B2 (ja) （ｒ，ｒ）−フェノテロールおよび（ｒ，ｒ）−または（ｒ，ｓ）−フェノテロール類似体の調製物ならびにうっ血性心不全の治療におけるそれらの使用
JP6130495B2 (ja) カンナビノイド受容体活性関連障害及び疾患を調節する方法
JP2009527501A (ja) Ｓ１ｐ受容体アゴニストとしてのフェニル−シクロアルキル誘導体およびフェニル−複素環誘導体
US20180042867A1 (en) Methods of treating cancer
US20190076379A1 (en) Methods of treating breast cancer
WO2017059268A1 (en) Methods of reducing chemoresistance and treating cancer
US20170172944A1 (en) Methods of treating melanoma
WO2018140923A1 (en) Methods of treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150507

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151106

R150 Certificate of patent or registration of utility model

Ref document number: 5837890

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250